SBIR/STTR Research Award

IN 1972, THE CHINESE ISOLATED AND CHARACTERIZED ARTEMISININ,AN ANTIMALARIAL DRUG PRESENT IN THE CHINESE HERB QINGHAO (ARTEMISIA ANNUA).

Award identifier 9755474ac3a220d66482cde4592bde0c4922266e7e53e26c101e181c38123483Awarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1986

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
BIOQUAL, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
CK9LGQ7EBNN8
Solicitation number
Not reported
Topic code
Not reported

Research abstract

IN 1972, THE CHINESE ISOLATED AND CHARACTERIZED ARTEMISININ,AN ANTIMALARIAL DRUG PRESENT IN THE CHINESE HERB QINGHAO (ARTEMISIA ANNUA). THIS HERB HAS BEEN USED FOR MALARIA THERAPY IN CHINA FOR OVER 1,000 YEARS. IN THE DEVELOPING COUNTRIES OF THE WORLD IT HAS BEEN ESTIMATED THAT IN EXCESS OF 150 MILLION CASES OF MALARIA EXIST. ALARMINGLY, THIS FACT IS COUPLED WITH THE APPARENT SPREAD OF STRAINS OF PLASMODIUM FALCIPARUM WHICH ARE RESISTANT TO CHLOROQUINE ANDTO ALTERNATIVE DRUGS (PYRIMETHAMINE/SULFONAMIDE COMBINATIONS). STUDIES HAVE SHOWN THAT ARTEMISININ HAS A HIGH LEVEL OF SCHIZONTICIDAL ACTIVITY AGAINST THE CHLOROQUINE-RESISTANT MALARIA AND IS NON-TOXIC; HOWEVER, ARTEMISININ OCCURS AT VERY LOW LEVELS IN A. ANNUA. THE OBJECTIVE OF THIS PHASE I PROPOSAL IS TO DEVELOP A MONOCLONAL ANTIBODY TO ARTEMISININ. THE ANTIBODY WILL THEN BE USED TO SELECT PLANTS WHICH ARE HIGH YIELDERS OF ARTEMISININ. THIS SELECTION WILL LEAD TO PHASE II CULTIVATION INITIALLY USING PLANT TISSUE CULTURE OF THESE SELECTED "HIGH YIELDERS." THIS HAS IMMEDIATE COMMERCIAL APPLICATION IN THE EFFORTS AGAINST MALARIA IN THAT HIGH- YIELDING PLANTS MAY BE PROPAGATED TO PROVIDE A SOURCE OF ARTEMISININ LARGE ENOUGH FOR USE AS A DRUG. THE MONOCLONAL ANTIBODY COULD FURTHER BE USED IN BIOAVAILABILITY, PHARMAKINETIC, AND DRUG MONITORING STUDIES.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

11 SBIR/STTR records share this UEI (1983–2001). Reported award amounts total $1,646,185. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Contractor profile

BIOQUAL, INC.

Historical federal award activity, when published, is on that contractor profile. Matched by UEI only.

Agency intelligence

Department of Health and Human Services

NAICS intelligence

This classification comes from the contractor profile, not from the SBIR award record.

Contractor industry classification NAICS 541512

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.